U.S. FDA approves bristol-myers squibb devens biologics manufacturing facility for production of orencia (abatacept)

Bristol Myers-Squibb, 05/16/2012

Bristol–Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA (abatacept).

Print Article Summary Cat 2 CME Report